Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid membrane remodeling by myristic acid treatment reverses Parkinson's disease α-synuclein phenotypes in patient neurons.

npj metabolic health and disease·2026
Same author

Higher-molecular-weight a-synuclein oligomers are increased in the brain cytosol of patients with dementia with Lewy bodies.

NPJ Parkinson's disease·2026
Same author

Sex-specific genetic regulation of proteomics in cerebrospinal fluid uncovers genetic causes for sex differences in neurodegeneration.

medRxiv : the preprint server for health sciences·2025
Same author

Parkinson disease is a fatty acidopathy.

Nature reviews. Neurology·2025
Same author

TDP-43 proteinopathies and neurodegeneration: insights from Caenorhabditis elegans models.

The FEBS journal·2025
Same author

GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy.

Research square·2025
Same journal

The Biology of Malaria Parasite Liver Infection.

Cold Spring Harbor perspectives in medicine·2026
Same journal

The Interaction between Diabetes Mellitus and Tuberculosis: Epidemiology, Screening, and Clinical Management.

Cold Spring Harbor perspectives in medicine·2026
Same journal

New Malaria Prevention Modalities: Long-Acting Interventions Beyond Vaccines.

Cold Spring Harbor perspectives in medicine·2026
Same journal

From Parasite to Pill: Harnessing Biology for Breakthroughs in Antimalarial Drug Discovery.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Malaria Parasite Genomics: Decentralization, Diversification, and Development Goals.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Tuberculosis Infection: Diagnosis and Management.

Cold Spring Harbor perspectives in medicine·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Deciphering Alzheimer disease.

Dennis Selkoe1, Eckhard Mandelkow, David Holtzman

  • 1Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. dselkoe@rics.bwh.harvard.edu

Cold Spring Harbor Perspectives in Medicine
|February 9, 2012
PubMed
Summary
This summary is machine-generated.

Alzheimer disease impairs intellect and emotional well-being. Recent advances in biochemical pathology and human genetics offer hope for developing effective Alzheimer disease therapeutics.

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Related Experiment Videos

Last Updated: May 25, 2026

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Alzheimer disease (AD) is a neurodegenerative disorder characterized by progressive cognitive and emotional decline.
  • The underlying biochemical pathology and genetic factors contributing to AD are complex and not fully understood.

Purpose of the Study:

  • To review recent advances in understanding the biochemical pathology and human genetics of Alzheimer disease.
  • To explore the potential for developing effective therapeutic agents for Alzheimer disease based on these advances.

Main Methods:

  • Literature review of recent research in Alzheimer disease.
  • Analysis of biochemical and genetic studies related to Alzheimer disease.
  • Synthesis of findings to identify therapeutic targets.

Main Results:

  • Significant progress has been made in elucidating the biochemical pathways implicated in Alzheimer disease.
  • Key genetic risk factors for Alzheimer disease have been identified, providing insights into disease mechanisms.
  • These advances highlight novel targets for therapeutic intervention.

Conclusions:

  • Recent breakthroughs in Alzheimer disease research offer substantial promise for the development of effective treatments.
  • Targeting specific biochemical pathways and genetic factors may lead to novel therapeutic strategies for Alzheimer disease.